# US 10,441,687 B2 · Wnt/beta-catenin inhibitor-eluting endovascular stent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,441,687 B2
- Document ID: US10441687B2
- Status: Granted
- Kind: B2
- Application number: 15/028,449
- Filed: 2014-11-05
- Published: 2016-09-15
- Granted: 2019-10-15
- Earliest claimed: 2013-11-13
- Assignees: Albert Einstein College of Medicine
- Applicants: Albert Einstein College of Medicine, Inc.
- Inventors: Nicholas Ernst Smit Sibinga; Dario Fernando Riascos-Bernal
- Web page: https://patentgrep.com/patent/US10441687B2

## CPC

- A61L 31/10: Macromolecular materials
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61L 2300/432: Inhibitors, antagonists (A61L2300/402 - A61L2300/43 take precedence)
- A61L 2420/06: Coatings containing a mixture of two or more compounds
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

A product comprising a stent for a human blood vessel which comprises (i) a scaffold which is impregnated with, adsorbed with, or coated with an inhibitor of a Wnt/p-catenin pathway, or (ii) a scaffold coated with a polymer, which polymer is impregnated with, adsorbed with, or coated with an inhibitor of a Wnt/p-catenin pathway, and methods of use to reduce the risk of restenosis.

## Claims

### Claim 1

A product comprising a stent for a human blood vessel which comprises (i) a scaffold coated with a polymer, which polymer is impregnated with, adsorbed with, or coated with an inhibitor of a Wnt/β-catenin pathway, or (ii) a scaffold which is impregnated with, adsorbed with, or coated with, an inhibitor of a Wnt/β-catenin pathway, wherein the inhibitor comprises

### Claim 2 (depends on 1)

The product of claim 1, wherein the stent is a shaped to be suitable as an endovascular stent.

### Claim 3 (depends on 1)

The product of claim 1, wherein at least 50% of the inhibitor of a Wnt/β-catenin pathway elutes from the stent.

### Claim 4 (depends on 1)

The product of claim 1, wherein at least 90% of the inhibitor of a Wnt/β-catenin pathway elutes from the stent over a time period of 1 to 150 days.

### Claim 5 (depends on 1)

The product of claim 1, wherein the stent comprises a scaffold impregnated with, adsorbed with, or coated with, an inhibitor of a Wnt/β-catenin pathway.

### Claim 6 (depends on 1)

The product of claim 1, wherein the stent comprises a scaffold coated with a polymer impregnated with, adsorbed with, or coated with an inhibitor of a Wnt/β-catenin pathway.

### Claim 7 (depends on 6)

The product of claim 6, wherein the inhibitor of a Wnt/β-catenin pathway is adsorbed within the polymer and/or adsorbed to a surface of the polymer.

### Claim 8 (depends on 6)

The product of claim 6, wherein the inhibitor of a Wnt/β-catenin pathway is coated on the polymer.

### Claim 9 (depends on 6)

The product of claim 6, wherein the polymer is not prothrombotic.

### Claim 10 (depends on 6)

The product of claim 6, wherein the polymer comprises one or more of poly(n-butyl methacrylate), poly(ethylene-co-vinyl acetate), poly(styrene-b-isobutylene-b-styrene) or poly(vinylidene fluoride-co-hexafluoropropylene).

### Claim 11 (depends on 6)

The product of claim 6, wherein the polymer comprises phosphorylcholine.

### Claim 12 (depends on 1)

The product of claim 1, wherein the polymer is biodegradable.

### Claim 13 (depends on 1)

The product of claim 1, wherein the stent is bioresorbable.

### Claim 14 (depends on 1)

A method for performing an angioplasty in a mammalian subject comprising surgically inserting the stent of claim 1 into the a vascular vessel and expanding the stent therein so as perform the angioplasty.

### Claim 15 (depends on 1)

A method for reducing restenosis in a vascular vessel at risk for restenosis of a mammalian subject, comprising surgically inserting the stent of claim 1 into the lumen of the vascular vessel at the site deemed at risk of restenosis, so as to reduce the risk of restenosis.

### Claim 16 (depends on 14)

The method of claim 14, wherein the vascular vessel is not a CNS vascular vessel.

### Claim 17 (depends on 14)

The method of claim 14, wherein the vascular vessel is a coronary vascular vessel.

### Claim 18 (depends on 14)

The method of claim 14, wherein the subject has atherosclerotic disease of the vascular vessel.

### Claim 19 (depends on 14)

The method of claim 14, wherein the subject has undergone an angioplasty of the vascular vessel.